Business Wire

ABB: Our Way forward


ABB will be hosting an investor webcast at 14:00 CEST today, June 10, at which CEO, Björn Rosengren, will be giving his initial impressions on the Group’s strategy since he joined the company at the beginning of the year, as well as details on his immediate priorities. Highlights will include:

– ABB-OS evolves into new operating model ABB Way

– Clear focus on decentralized business model and 18 fully accountable divisions

– Prioritization of stability and profitability before growth

– Active portfolio management to play key role

– Combination of COVID-19 and oil price drop will lead to challenges over the coming quarters

– Group mid-term financial targets remain in place

– Divestment of Power Grids on track to be completed end Q2, 2020

– ABB on track to deliver $500 million ABB-OS cost savings

“After my first 100 days as CEO, I can truly say: ABB has a good foundation to build on. Our technology and products are well aligned to key market trends and customer needs such as the electrification of transport, automated manufacturing, digital solutions and increased sustainable productivity,” said Björn Rosengren. “We will now leverage this strong position to create superior value for our customers, employees and shareholders. We will do this by evolving our decentralized business model, strengthening our performance management culture, putting stability and profitability before growth, and driving active portfolio management.”

The company’s mid-term financial targets of a 3-6 percent comparable revenue growth per year, an operational EBITA margin of 13-16 percent, ~100 percent cash conversion rate, 15-20 percent ROCE and EPS growing at a faster rate than revenue growth, remain in place. An update on the strategy, including long-term 2030 sustainability targets, will be provided later this year at the Group’s Capital Market Day in November 2020.

Currently, ABB is still facing challenging quarters ahead due to the COVID-19 global pandemic and a drop in the oil price. This has led to a decline in demand, for example, in the automotive and power generation end markets, while travel restrictions and supply chain constraints also have an impact on business. Nevertheless, the Chinese market continues to recover, while the transport, food & beverage and data center sectors remain relatively resilient.

“The health and safety of all our stakeholders remains the key priority in these difficult times, while we are also intensifying our efforts to mitigate the crisis by increasing our number of virtual customer visits, adjusting production capacity to demand and managing cash tightly,” said Rosengren.

At today’s event, CFO Timo Ihamuotila will comment on ABB’s capital allocation priorities, which remain unchanged. The sale of the Power Grids business to Hitachi is expected to be completed at the end of the second quarter of 2020 and ABB remains committed to a share buyback program using net cash proceeds from the transaction. ABB is planning to execute this in an efficient and responsible way, taking account of the prevailing circumstances. Cash will also be returned to shareholders in the form of rising sustainable dividends per share and ABB aims to retain a “single A” credit rating.

Creating superior value through new operating model ABB Way

A key element of ABB’s strategy to create superior value is the ongoing decentralization of the business model. ABB has successfully discontinued its longstanding matrix organization over the last 18 months, with more responsibility shifted to the four business areas of Electrification, Industrial Automation, Motion and Robotics & Discrete Automation.

Going forward, a new operating model called ABB Way will provide a governance framework of processes and policies, connecting the business areas and divisions to the corporate center and uniting the Group under the ABB brand. ABB Way is evolving from the current ABB-OS, which is on track to deliver the targeted $500 million cost savings, with the full run-rate benefit during 2021.

After having been successfully launched in 2016, the ABB Ability™ digital platform will also be managed by the business areas and no longer in the corporate center. This will enable them to create software solutions more efficiently and quickly. ABB Ability™ has more than 160 digital solutions, boasting top-tier software partnerships with Microsoft, Hewlett Packard Enterprises and Ericsson, for example.

In a further step of moving operating activities even closer to the customer, ABB will empower 18 divisions comprised within the four business areas. More details on the divisions, as well as updated strategies for the business areas, will be provided at the Capital Markets Day in November 2020. ABB will continue to report its financial results based on the four business areas.

“We will strengthen our performance management through a new scorecard system based on a very transparent and standardized set of KPIs. Here, I expect our management to focus on having a stable structure and profitability before embarking on growth,” said Rosengren. “The benchmark is for each of the divisions to be number one or two in its respective market segment.”

As part of this new divisional focus, ABB will also further strengthen its ongoing portfolio review process to ascertain whether ultimately ABB is the best owner in terms of strategic attractiveness, value creation potential and structural fit.

“Portfolio management will play an even more important role going forward and we will not shy away from fixing, exiting or growing divisions,” said Rosengren. “At the same time, no major acquisitions are planned by ABB in the mid-term.”

As part of the ABB Way, corporate functions will focus on financial, strategic and governance activities in the future and have a reduced headcount of less than 1,000 employees worldwide. At the beginning of 2019, roughly 18,000 employees were still in corporate functions, the majority of whom were then gradually transferred into the business areas.

ABB (ABBN: SIX Swiss Ex) is a leading global engineering company that energizes the transformation of society and industry to achieve a more productive, sustainable future. By connecting software to its electrification, robotics, automation and motion portfolio, ABB pushes the boundaries of technology to drive performance to new levels. With a history of excellence stretching back more than 130 years, ABB’s success is driven by 144,000 talented employees in over 100 countries.

Important notice about forward-looking information

This press release includes forward-looking information and statements which are based on current expectations, estimates and projections about the factors that may affect our future performance, including the economic conditions of the regions and industries that are major markets for ABB. These expectations, estimates and projections are generally identifiable by statements containing words such as “anticipates”, “expects,” “believes,” “estimates,” “plans”, “targets”, “on track” or similar expressions. However, there are many risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking information and statements made in this press release and which could affect our ability to achieve any or all of our stated targets. The important factors that could cause such differences include, among others, business risks associated with the volatile global economic environment and political conditions, costs associated with compliance activities, market acceptance of new products and services, changes in governmental regulations and currency exchange rates and such other factors as may be discussed from time to time in ABB Ltd’s filings with the U.S. Securities and Exchange Commission, including its Annual Reports on Form 20-F. Although ABB Ltd believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.

Contact information

For more information please contact:
Media Relations
Phone: +41 43 317 71 11

Investor Relations
Phone: +41 43 317 71 11

Affolternstrasse 44
8050 Zurich

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LintonPharm Announces Authorization From China Health Authority to Proceed With a Global Phase 3 Trial Evaluating Catumaxomab in Advanced Gastric Cancer15.7.2020 23:30:00 EESTPress release

LintonPharm Co. Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T-cell engaging bispecific antibodies for cancer immunotherapy, today announced the China National Medical Products Administration (NMPA) authorized the company to proceed with a Phase III trial ( NCT04222114) for catumaxomab in patients with peritoneal carcinomatosis, a form of advanced gastric cancer that has spread to the tissue that lines the abdominal cavity. The two-stage, multi-center, open-label, randomized, controlled registrational clinical trial will evaluate the safety and efficacy of an intraperitoneal infusion of the bi-specific antibody catumaxomab into the abdominal cavity in patients with peritoneal carcinomatosis. LintonPharm also recently received Clinical Trial Application (CTA) authorization for the same indication from the Taiwan Ministry of Health and Welfare (MOHW) and the Korea Ministry of Food and Drug Safety (MFDS). “We are excited to

Xerox Launches ConnectKey-Enabled AltaLink Digital Workplace Assistant15.7.2020 19:47:00 EESTPress release

Xerox announced its new Xerox AltaLink® C8100 and Xerox AltaLink B8100 Series multi-function printers (MFPs), that can better support today’s flexible work environment and help companies speed their digital transformation with access to the ConnectKey® ecosystem of apps. This press release features multimedia. View the full release here: The tablet-like user interface allows for easy, familiar interaction or the user can choose to print from their mobile devices. (Photo: Business Wire) In addition to its printing capabilities, the AltaLink 8100 series helps speed workplace digitization with ultra-fast scanning of up to 270 images per minute and Optical Character Recognition that allows clients to extract more value from information. Combined with ConnectKey apps, including connections to the most popular cloud solutions, these printers can support a key area of focus for businesses as they shift from physical to digital enterpri

Bureau Veritas Launches a New Solution to Improve Supply Chain Resilience15.7.2020 18:45:00 EESTPress release

Bureau Veritas , a world leader in testing, inspection and certification (TIC) services, is launching Supply-R, a solution designed to meet companies’ new challenges relating to supplier network reliability and ensuring business continuity in all circumstances. Organizations learned multiple lessons during the first half of 2020 on the resilience of global supply chains and their ability to face disruptions. There is an urgent need from many companies to reassess their supply chain risk, based on factual data from the field, to make sure that all elements are properly addressed, assessed and visible. Bruno Ferreyra, Executive Vice-President at Bureau Veritas, commented: "Economic globalization means supply chains include more suppliers and intermediaries than before, and they are scattered around the globe. This makes each step, process and stakeholder in the manufacturing chain harder to track. Our goal is to support businesses, mapping out their supply chains to give them complete co

VALBIOTIS Announces the First Patient First Visit in the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63 to Reduce Type 2 Diabetes Risk Factors15.7.2020 18:40:00 EESTPress release

Regulatory News: VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME eligible) a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the First Patient First Visit in the international Phase II/III REVERSE-IT clinical study designed to assess TOTUM-63 for the reduction of Type 2 Diabetes metabolic risk factors. Murielle CAZAUBIEL, member of the Management Board and Director of Development and Medical Affairs at VALBIOTIS, comments: "The first visit of this first subject, a few days after obtaining both ANSM 1 approval and the favorable decision from the CPP 2 , marks the concrete launch of the REVERSE-IT study, the results of which are expected in mid-2022. We are right on schedule and are delighted to be able to enter the operational phase of this major study so quickly. We also welcome the enthusiasm and commitment of all the partner investigation centers." Dr Hans-Juergen WOERLE, Chief Scientific and Medical

Octapharma Reports Positive Data from octagam® Usage in Critically Ill COVID-19 Patients15.7.2020 18:04:00 EESTPress release

Topline results from a retrospective study in 93 critically ill COVID-19 patients have become available. The data shows that IVIG treatment reduces inflammation, which is associated with poor clinical outcomes and death, and points to an increase in survival, in critically ill COVID-19 patients, when compared to a control group. The study was conducted at the Istanbul University Hospital, Turkey, under the lead of Prof. Dr. Figen Esen. In critically ill COVID-19 patients, the cause of death often implicates an abnormal pulmonary immune response. This abnormal immune response is characterized by high levels of inflammatory markers, which are associated with poor clinical outcomes.1, 2 Acute respiratory distress syndrome (ARDS) and multiorgan failure are major causes of mortality in COVID-19 patients.3 High levels of pro-inflammatory cytokines and chemokines are part of a severe inflammatory response known as a “cytokine storm” which may cause multiple organ dysfunction and ARDS in criti

European Commission approves third nintedanib indication in pulmonary fibrosis115.7.2020 16:34:00 EESTPress release

Boehringer Ingelheim today announced that the European Commission (EC) has approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).1 The approval comes after the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in May 2020.3 The U.S. Food and Drug Administration (FDA), Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) recently approved nintedanib as the first treatment for the same patient population.4,5,6 Interstitial lung diseases encompass a large group of more than 200 disorders that may involve the threat of pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function.7 People living with fibrosing ILD can develop a progressive phenotype, leading to lung function decline, deterioration in quality of life and early mortality simila

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom